VIP (Vasoactive Intestinal Peptide) (VIP)
Research
Preclinical
Neuropeptide with wide-ranging effects on the nervous system, immune function, and circadian rhythm.
Key Data
- Research Status
- Preclinical
- Half-Life
- ~2 minutes
- Administration
- Intranasal or subcutaneous
- Typical Dosage
- 50-100 mcg intranasal
Mechanism of Action
Activates VPAC1 and VPAC2 receptors throughout the body for multiple physiological effects.
Reported Benefits
- Neuroprotection
- Anti-inflammatory
- Circadian regulation
- Immune modulation
All information is presented for Research Use Only (RUO). Not medical advice.